Drugs / CM336
Trials 19
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT07407010 | Jun 2026 → May 2027 expected | refractory plasma cell neoplasm | Institute of Hematology & Blood Diseases Hospital, China | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07642843 | Jun 2026 → Apr 2028 expected | Sjogren syndrome | Keymed Biosciences Co.Ltd | Not yet recruiting | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT07687004 | Aug 2026 → Aug 2027 expected | plasma cell myeloma | Institute of Hematology & Blood Diseases Hospital, China | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07175493 | Nov 2025 → Nov 2027 expected | Evans syndrome | Keymed Biosciences Co.Ltd | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05299424 | Aug 2022 → Dec 2026 expected | plasma cell myeloma | Keymed Biosciences Co.Ltd | Recruiting | No outcome recorded |
| Phase 211 trials | ||||||
| Phase 2 | NCT07830485 | Oct 2026 → Apr 2029 expected | plasma cell myeloma | Institute of Hematology & Blood Diseases Hospital, China | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07652905 | Sep 2026 → Jun 2029 expected | plasma cell leukemia | Institute of Hematology & Blood Diseases Hospital, China | Recruiting | No outcome recorded |
| Phase 2 | NCT07585760 | Sep 2026 → May 2028 expected | plasma cell myeloma | Institute of Hematology & Blood Diseases Hospital, China | Recruiting | No outcome recorded |
| Phase 2 | NCT07648459 | Jun 2026 → Jul 2027 expected | plasma cell myeloma | Institute of Hematology & Blood Diseases Hospital, China | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07409454 | Mar 2026 → Dec 2027 expected | plasma cell myeloma | Institute of Hematology & Blood Diseases Hospital, China | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07151690 | Sep 2025 → Dec 2026 expected | AL amyloidosis | Institute of Hematology & Blood Diseases Hospital, China | Recruiting | No outcome recorded |
| Phase 2 | NCT07115667 | Aug 2025 → Dec 2026 expected | primary plasmacytoma of the bone, solitary osseous plasmacytoma | Institute of Hematology & Blood Diseases Hospital, China | Recruiting | No outcome recorded |
| Phase 2 | NCT07115654 | Aug 2025 → Dec 2026 expected | POEMS syndrome | Institute of Hematology & Blood Diseases Hospital, China | Recruiting | No outcome recorded |
| Phase 2 | NCT07039578 | Jul 2025 → Jun 2026 overdue | AL amyloidosis | Keymed Biosciences Co.Ltd | Recruiting | No outcome recorded |
| Phase 2 | NCT06900010 | Apr 2025 → Jan 2027 expected | autoimmune bullous skin disease | Shandong First Medical University | Recruiting | No outcome recorded |
| Phase 2 | NCT06799611 | Mar 2025 → Jan 2026 overdue | autoimmune thrombocytopenia | Institute of Hematology & Blood Diseases Hospital, China | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07181239 | Sep 2025 → Sep 2027 expected | plasma cell myeloma | Keymed Biosciences Co.Ltd | Not yet recruiting | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT06769555 | Jan 2025 → Aug 2026 | AL amyloidosis | Institute of Hematology & Blood Diseases Hospital, China | Withdrawn | No outcome recorded |
| — | NCT06745687 | Dec 2024 → Aug 2026 overdue | smoldering plasma cell myeloma | Institute of Hematology & Blood Diseases Hospital, China | Not yet recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2024-10-30 | Keymed Biosciences Co.Ltd | Results 疗效优异！康诺亚BCMAxCD3双抗CM336 I/II期临床研究最新数据在第66届美国血液学会(ASH)年会发布 keymedbio.com ↗
剂量递增阶段中位随访时间12.1个月， 52% ( 12/23)的受试者达到严格意义的完全缓解(sCR)或完全缓解(CR) 。 |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-06-05 | Keymed Biosciences Co.Ltd | 康诺亚NewCo合作公司Ouro Medicines成功完成与吉利德科学并购交易，潜在同类最优TCE CM336/OM336全球开发进入新阶段 keymedbio.com ↗ |
| 2026-06-05 | Keymed Biosciences Co.Ltd | 康诺亚NewCo合作公司Ouro Medicines成功完成与吉利德科学并购交易，潜在同类最优TCE CM336/OM336全球开发进入新阶段 keymedbio.com ↗ |
| 2026-03-24 | Keymed Biosciences Co.Ltd | 康诺亚NewCo合作公司Ouro Medicines与吉利德科学达成收购协议，加速推进潜在同类最优TCE CM336/OM336全球开发 keymedbio.com ↗ |
| 2024-10-30 | Keymed Biosciences Co.Ltd | 疗效优异！康诺亚BCMAxCD3双抗CM336 I/II期临床研究最新数据在第66届美国血液学会(ASH)年会发布 keymedbio.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 19 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CM-336 | “The purpose of this study is to evaluate the safety and efficacy of CM-336, which is a BCMA/CD3 BiTE, in the treatment of high risk smoldering multiple myeloma.” NCT06745687 ↗19“Anti-BCMA/CD3 bispecific antibody (CM336) will be administered via a subcutaneous injection (SC).” NCT07648459 ↗ “Anti-BCMA/CD3 bispecific antibody (CM336) will be administered via a subcutaneous injection (SC).” NCT07409454 ↗ “CM336 is a bispecific T-cell engager targeting B-cell maturation antigen (BCMA) and CD3.” NCT07151690 ↗ |
| Action | Deplete | “CM336 can eliminate BCMA-positive B cells and plasma cells through the above mechanism” NCT06799611 ↗ |
| Modality | Monoclonal antibody | “CM336 (BCMA/CD3 Bispecific Antibody)” NCT07039578 ↗ |
| Route | Subcutaneous | “CM336 will be administered subcutaneously (SC) once a week (QW).” NCT05299424 ↗ |